Nippon India Nifty Pharma ETF
Nippon India Nifty Pharma ETF portfolio holdings, Oct 2026: 20 stocks, ₹1,756 cr in listed equity, from Nippon India Mutual Fund's monthly disclosure; changes by share count against Sep 2026.
Fund managers: Jitendra Tolani
Benchmark: Nifty Pharma TRI · Riskometer: Very High · Allotted 2 Jul 2021
Source: AMFI scheme summary document
The scheme's yearly running cost as a % of its assets, taken out of the NAV a little each day. A regular plan costs more: it pays a distributor's commission.
Category median: direct 0.26 %, regular 0.32 % (213 schemes)
Of this, the base expense ratio, the part SEBI caps: direct 0.18 %. The rest is brokerage, transaction costs and statutory levies such as GST and STT, as AMFI's file lists them.
A year, as of 20 Nov 2026. Source: AMFI · Glossary: TER
20 stocks, Oct 2026.
As the AMC's file prints % of NAV. The top 10 stocks together: 78.6%.
This month: Oct 2026
compared with Sep 2026 · by share countMoves, Oct 2026
How many stocks the scheme bought into, added to, cut or sold out of this month, by share count, so a price move alone never counts.
- New0
- Added0
- Trimmed20
- Exited0
Asset mix, Oct 2026
How much of the fund sits in listed shares; the rest is foreign shares, debt, money market, cash and other assets.
- Listed equity100.0%
- Rest, not itemised0.0%
Rest = foreign shares, debt, money market, cash, REIT/InvIT units and other assets.
Sectors and top 10, Oct 2026
Sector mix, Oct 2026
How the scheme's equity is spread across sectors at month end.
- 100.0%
AMFI's 22 sectors; one sector per stock, from the fund houses' industry labels.
Large, mid and small cap, Oct 2026
How the scheme's equity splits across large, mid and small companies, on AMFI's list.
- Mid Cap47.1%
- Large Cap45.3%
- Small Cap7.6%
AMFI's list of Jun 2026.
Top 10 holdings
Its ten largest stocks, each as a share of the fund.
- 18.61%
- 12.28%
- 9.26%
- 8.15%
- 7.67%
- 6.71%
- 4.83%
- 4.59%
- 3.42%
- 3.05%
As the AMC's file prints % of NAV.
| Stock | Change | Shares before | Shares now | Difference | Change % | Value of change | Value now |
|---|---|---|---|---|---|---|---|
| SUNPHARMA | Trimmed | 18.64 lakh | 18.39 lakh | −25,842 | −1.4% | −₹4.6 cr | ₹327 cr |
| DIVISLAB | Trimmed | 2.24 lakh | 2.21 lakh | −3,186 | −1.4% | −₹3.1 cr | ₹216 cr |
| LAURUSLABS | Trimmed | 6.86 lakh | 6.76 lakh | −9,558 | −1.4% | −₹2.3 cr | ₹163 cr |
| DRREDDY | Trimmed | 10.74 lakh | 10.59 lakh | −14,868 | −1.4% | −₹2.0 cr | ₹143 cr |
| CIPLA | Trimmed | 9.91 lakh | 9.77 lakh | −13,688 | −1.4% | −₹1.9 cr | ₹135 cr |
| TORNTPHARM | Trimmed | 2.59 lakh | 2.56 lakh | −3,540 | −1.4% | −₹1.6 cr | ₹118 cr |
| LUPIN | Trimmed | 4.28 lakh | 4.22 lakh | −5,900 | −1.4% | −₹1.2 cr | ₹84.8 cr |
| AUROPHARMA | Trimmed | 4.87 lakh | 4.80 lakh | −6,726 | −1.4% | −₹1.1 cr | ₹80.7 cr |
| GLENMARK | Trimmed | 2.65 lakh | 2.61 lakh | −3,658 | −1.4% | −₹0.84 cr | ₹60.1 cr |
| ZYDUSLIFE | Trimmed | 4.36 lakh | 4.30 lakh | −6,018 | −1.4% | −₹0.75 cr | ₹53.6 cr |
| ALKEM | Trimmed | 1.06 lakh | 1.05 lakh | −1,416 | −1.3% | −₹0.72 cr | ₹53.6 cr |
| MANKIND | Trimmed | 2.00 lakh | 1.97 lakh | −2,714 | −1.4% | −₹0.68 cr | ₹49.1 cr |
| IPCALAB | Trimmed | 2.45 lakh | 2.41 lakh | −3,422 | −1.4% | −₹0.66 cr | ₹46.5 cr |
| GLAND | Trimmed | 1.40 lakh | 1.38 lakh | −2,048 | −1.5% | −₹0.63 cr | ₹42.8 cr |
| BIOCON | Trimmed | 12.27 lakh | 12.10 lakh | −16,992 | −1.4% | −₹0.60 cr | ₹42.6 cr |
| SAILIFE | Trimmed | 2.44 lakh | 2.40 lakh | −3,422 | −1.4% | −₹0.53 cr | ₹37.4 cr |
| AJANTPHARM | Trimmed | 80,268 | 79,248 | −1,020 | −1.3% | −₹0.36 cr | ₹27.8 cr |
| WOCKPHARMA | Trimmed | 1.45 lakh | 1.43 lakh | −2,006 | −1.4% | −₹0.38 cr | ₹27.3 cr |
| PPLPHARMA | Trimmed | 10.94 lakh | 10.79 lakh | −15,104 | −1.4% | −₹0.36 cr | ₹25.8 cr |
| ABBOTINDIA | Trimmed | 9,176 | 9,058 | −118 | −1.3% | −₹0.30 cr | ₹23.2 cr |
Value of change = the difference in shares × this month's price in the AMC's file. Value now = the whole holding's market value in that file (an exit: last month's).
Show all 20 stocksShow the first 15
Equity rows as disclosed, Oct 2026. Source: Nippon India Mutual Fund monthly portfolio. Report a wrong number
Large, mid and small caps, % of net assets, last 12 months
AMFI list in force each month
| Month | Large | Mid | Small | Not in AMFI's list | AMFI list |
|---|---|---|---|---|---|
| Oct 2026 | 45.3% | 47.1% | 7.6% | 0.0% | Jun 2026 |
| Sep 2026 | 46.3% | 46.1% | 7.5% | 0.0% | Jun 2026 |
| Aug 2026 | 47.8% | 45.0% | 7.1% | 0.0% | Jun 2026 |
| Jul 2026 | 47.6% | 45.5% | 6.7% | 0.0% | Jun 2026 |
| Jun 2026 | 53.4% | 37.9% | 8.6% | 0.0% | Dec 2025 |
| May 2026 | 53.9% | 37.5% | 8.5% | 0.0% | Dec 2025 |
| Apr 2026 | 55.6% | 36.9% | 7.5% | 0.0% | Dec 2025 |
| Mar 2026 | 55.6% | 37.0% | 7.4% | 0.0% | Dec 2025 |
| Feb 2026 | 55.4% | 36.8% | 7.7% | 0.0% | Dec 2025 |
| Jan 2026 | 54.9% | 37.1% | 7.9% | 0.0% | Dec 2025 |
| Dec 2025 | 68.4% | 25.3% | 6.2% | 0.0% | Jun 2025 |
| Nov 2025 | 69.2% | 24.8% | 6.0% | 0.0% | Jun 2025 |
Equity holdings' % of net assets each month, by AMFI's cap list in force that month.
Portfolio turnover, from holdings
equity only · month-end snapshots
| Month | Bought | Sold | Turnover |
|---|---|---|---|
| Oct 2026 | ₹0.00 cr | ₹24.7 cr | 0.0% |
| Sep 2026 | ₹25.4 cr | ₹0.49 cr | 0.0% |
| Aug 2026 | ₹30.0 cr | ₹0.00 cr | 0.0% |
| Jul 2026 | ₹65.2 cr | ₹72.0 cr | 3.9% |
| Jun 2026 | ₹0.00 cr | ₹12.3 cr | 0.0% |
| May 2026 | ₹151 cr | ₹0.00 cr | 0.0% |
| Apr 2026 | ₹50.5 cr | ₹0.00 cr | 0.0% |
| Mar 2026 | ₹223 cr | ₹0.00 cr | 0.0% |
| Feb 2026 | ₹0.00 cr | ₹6.5 cr | 0.0% |
| Jan 2026 | ₹26.4 cr | ₹0.00 cr | 0.0% |
| Dec 2025 | ₹4.6 cr | ₹0.06 cr | 0.0% |
| Nov 2025 | ₹0.00 cr | ₹26.8 cr | 0.0% |
The lower of bought and sold over the average equity value, from month-end holdings; it can differ from the fund house's own figure.
| Period | Direct plan | Regular plan | Benchmark, as published by AMFI Nifty Pharma TRI |
|---|---|---|---|
| 1 year | — | +25.28 % | +25.59 % |
| 3 years | — | +21.97 % | +22.28 % |
| 5 years | — | +16.60 % | +16.87 % |
| Since launch | — | +14.02 % | — |
Past performance may not be sustained in future.
As AMFI's fund performance report prints them for "Nippon India Nifty Pharma ETF"; this site computes no benchmark figure of its own.
How it is computed: NAV to NAV
Nippon India Nifty Pharma ETF - Direct Plan: these run to the newest NAV stored (20 Nov 2026) and are computed here from AMFI's NAV files; AMFI's figures above run to 19 Nov 2026, so the two differ by the days in between.
| Period | Return | From | To |
|---|---|---|---|
| 1 year | +25.57 % in total | 20 Nov 2025 · NAV ₹23.2424 | 20 Nov 2026 · NAV ₹29.1863 |
| 3 years | +22.02 % a year, compounded | 20 Nov 2023 · NAV ₹16.0545 | 20 Nov 2026 · NAV ₹29.1863 |
| 5 years | +16.60 % a year, compounded | 18 Nov 2021 · NAV ₹13.5231 | 20 Nov 2026 · NAV ₹29.1863 |
| Since first NAV | +14.02 % a year, compounded | 6 Jul 2021 · NAV ₹14.4098 | 20 Nov 2026 · NAV ₹29.1863 |
Source: AMFI NAV files (plan code 149008). How to read Report a wrong number
Tracking error and tracking difference
index fund / ETF · as published by AMFI
| Tracking difference, Oct 2026 | Direct plan | Regular plan |
|---|---|---|
| 1 year | — | −0.30 % |
| 3 years | — | −0.32 % |
| 5 years | — | −0.27 % |
| Since launch | — | −0.28 % |
As AMFI publishes them against Nifty Pharma TRI. Source: AMFI tracking error and tracking difference. How to read
IDCW (dividend) history
0 declarations · as of 2 Nov 2026 · Source: AMFI
IDCW (formerly "dividend") declared per unit of each IDCW plan, as AMFI lists it.
Rolling returns, Nippon India Nifty Pharma ETF - Direct Plan
weekly NAVs · Source: AMFI
| Window | Lowest | Median | Highest | Windows above zero |
|---|---|---|---|---|
| 1 year in total | −13.34 % 9 Sep 2021 to 16 Sep 2022 | +13.73 % 24 Jun 2022 to 30 Jun 2023 | +63.77 % 3 Mar 2023 to 7 Mar 2024 | 73 % of 226 windows ending 15 Jul 2022 to 20 Nov 2026 |
| 3 years a year, compounded | +12.36 % 16 Jul 2021 to 19 Jul 2024 | +20.37 % 18 Aug 2023 to 21 Aug 2026 | +27.03 % 19 May 2023 to 22 May 2026 | 100 % of 124 windows ending 12 Jul 2024 to 20 Nov 2026 |
Past performance may not be sustained in future.
Every 1-, 3- and 5-year window ending on a week's last NAV, lowest, middle and highest.
Standard deviation of weekly NAV changes × √52. 24 Nov 2023 to 20 Nov 2026, 156 weekly changes.
Source: AMFI
High 14 Oct 2021, low 17 Mar 2023; back at the high 28 Jul 2023.
Weekly NAVs since 9 Jul 2021. Measured on each week's last NAV, so a fall within a week can be deeper than shown.
Source: AMFI
Past performance may not be sustained in future.
Highest and lowest of 249 daily NAVs, 20 Nov 2025 to 20 Nov 2026, Nippon India Nifty Pharma ETF - Direct Plan.
Source: AMFI
Calendar-year returns, Nippon India Nifty Pharma ETF - Direct Plan
NAV to NAV · Source: AMFI
| Year | Return | From | To |
|---|---|---|---|
| 2025 | −2.46 % | 31 Dec 2024 · NAV ₹23.8601 | 31 Dec 2025 · NAV ₹23.2737 |
| 2024 | +39.59 % | 29 Dec 2023 · NAV ₹17.0930 | 31 Dec 2024 · NAV ₹23.8601 |
| 2023 | +34.44 % | 30 Dec 2022 · NAV ₹12.7138 | 29 Dec 2023 · NAV ₹17.0930 |
| 2022 | −10.86 % | 31 Dec 2021 · NAV ₹14.2628 | 30 Dec 2022 · NAV ₹12.7138 |
Past performance may not be sustained in future.
Change in the plan's NAV over each calendar year, last NAV to last NAV. Source: AMFI NAV files. How to read
Monthly SIP of ₹10,000, Nippon India Nifty Pharma ETF - Direct Plan
XIRR · Source: AMFI
| Period | Instalments | Paid in | Value | XIRR, a year |
|---|---|---|---|---|
| 1 year 1 Dec 2025 to 2 Nov 2026 | 12 | ₹1,20,000 | ₹1,41,252 20 Nov 2026 · NAV ₹29.1863 | +36.55 % |
Past performance may not be sustained in future.
₹10,000 on the first NAV of each month, valued at the newest NAV; no stamp duty, exit load or tax taken off.
Embed this card
Copy this into any web page. The image carries its source, date and a link back; it is redrawn each night.
Questions about Nippon India Nifty Pharma ETF
from the figures on this pageWhat are the top holdings of Nippon India Nifty Pharma ETF?
At Oct 2026 end, Nippon India Nifty Pharma ETF held 20 stocks (100.0% of the fund in equity). Largest: Sun Pharmaceutical Industries 18.61%, Divi's Laboratories 12.28%, Laurus Labs 9.26%, Dr. Reddy's Laboratories 8.15%, Cipla 7.67%; the top 10 make up 78.6%. Funds holding Sun Pharmaceutical Industries · Funds holding Divi's Laboratories · Funds holding Laurus Labs
What portfolio changes did Nippon India Nifty Pharma ETF make in Oct 2026?
Compared with Sep 2026, by share count: 0 new, 0 added, 20 trimmed, 0 exited. Largest by value: Sun Pharmaceutical Industries (trimmed), Divi's Laboratories (trimmed), Laurus Labs (trimmed), Dr. Reddy's Laboratories (trimmed).
Who manages Nippon India Nifty Pharma ETF?
AMFI's scheme summary document names Jitendra Tolani for Nippon India Nifty Pharma ETF (Nippon India Mutual Fund). Jitendra Tolani, fund manager portfolio
All schemes of Nippon India Mutual Fund →
Mutual fund investments are subject to market risks; read all scheme related documents carefully.